**Prevalence of methicillin resistance and virulence determinants of *Staphylococcus aureus* in diabetic foot ulcers**

Sumeet Sandhu, Irani Udesika Rathnayake, Flavia Huygens*

**INTRODUCTION**

Diabetes mellitus is the most commonly encountered health problem worldwide.\(^1\) Studies have shown that 6-8% of the adult population worldwide is diagnosed with diabetes.\(^2\) According to World Health Organization reports, the prevalence of this condition will double by the year 2025. It is the metabolic disorder, which damages target organs and is characterized by chronic hyperglycemia.\(^1\) One of the most common complications associated with diabetes is diabetic foot ulcer (DFU), which accounts for around 20% of hospital admissions around the world.\(^4,5\) Furthermore, DFUs are one of the most common causes of lower limb amputations, prolonged outpatient care and hospitalization.

It is estimated that about 15% of all the diabetic patients develop foot ulcers during their lifetime.\(^4,6\)

Infection is one of the complications associated with DFUs, and an infected DFU is also the second major cause of amputation.\(^3\) Bacterial colonization occurs in deep tissues once the protective layer of the skin is broken.\(^1\) Therefore, DFUs are highly prone to infections. Once the bacterial infection occurs, it rapidly spreads and leads to severe destruction of tissues that requires subsequent amputation.\(^1,6-9\) Despite the presence of various mixed (Gram-positive and Gram-negative) bacterial species in DFUs, the most frequently isolated species is *Staphylococcus aureus*.\(^1\) *S. aureus* is considered to be the major pathogen causing...
DFU infections and it is also one of the most adaptable human pathogens responsible for causing a wide range of illnesses.  

A major threat to public health is the increasing prevalence of antimicrobial resistance which occurs due to excess usage of antibiotics. In 15-30% of DFUs, methicillin-resistant *S. aureus* (MRSA) are isolated. Different factors are responsible for this resistance but mainly it is due to inappropriate antibiotic treatment and poor hygiene.Infrequent patient contact and follow-up has also contributed to resistance development as they may encourage the clinician to overprescribe. The virulence potential of *S. aureus* present in DFUs is also a factor, which can contribute to wound severity as these factors enables this pathogen to access and destroy the host tissue.

The aim of the present study was to detect the presence of *S. aureus* in infected DFUs along with its virulence and antibiotic resistance profiles. An understanding of the pathogenic and antibiotic resistance profiles of *S. aureus* in DFUs will assist health professionals to manage this ailment more efficiently by using targeted therapy.

**Aims and objectives**

- To detect the presence of *S. aureus* in DFU samples using molecular methods
- To determine the prevalence of MRSA in DFUs
- To determine the virulence profile of *S. aureus* in DFUs.

**METHODS**

DFU swab samples were collected from 30 patients at different time points (from March-October 2012) using the Z-swab technique. All swabs were kept at 4°C until transported to the laboratory, whereupon they were stored at −80°C until further analysis.

**DNA extraction**

DNA was extracted from *S. aureus* ATCC control strains (ATCC 29213 and USA 300) and patient swabs using an optimised Qiagen protocol as per manufacturer’s guidelines.

**Detection of *S. aureus* and its methicillin resistance and virulence determinants in DFUs**

The gene for *S. aureus* speciation was *mecA* and *mecA* for methicillin resistance. Virulence gene targets included: Panton–Valentine leukocidin (PVL), alpha toxin, exfoliatin factor A (*exfA*), fibronectin factor A (*fnbA*) and fibronectin factor B (*fnbB*). Primers were selected from previously published studies (Table 1). After primer optimization, DNA extracted from wound swabs was subjected to individual polymerase chain reaction (PCR) reaction conditions depending on the targeted gene.

**PCR reaction for *S. aureus* (**nucA**, **mecA**, **PVL**, **alpha toxin**, **exfA**, **fnbA** and **fnbB**)**

Each 25 µl PCR reaction contained 2 µl of DNA which was added to 23 µl of master mix containing 0.1 µl of Taq polymerase (Roche, Australia), 0.5 µl of dNTPs (Roche, Australia), 0.625 µl each of reverse and forward primers (Table 2) (Sigma Aldrich, Australia), 1.5 µl of MgCl2 (Roche, Australia), 2.5 µl of 10X PCR buffer (Roche, Australia) and 17.15 µl of water (DNAse and RNAse free - Life Technologies, Australia). PCR was performed using the program, including initial denaturation at 95°C for 10 mins, followed by 30 cycles of annealing and extension (72°C for 30 sec). An annealing temperature of 55°C was used for *mecA* and *mecA* gene amplification. 60°C was used as an annealing temperature for *alpha toxin*, *fnbA* and *fnbB* genes. *exfA* gene was amplified using an annealing temperature of 49°C. Final extension was carried out for 5 mins at 72°C. The PCR products were visualized using agarose gel (2%) electrophoresis. Gel images were captured using the GeneSnap program of G: BOX gel documentation system, Syngene Australia.

**RESULTS**

This study included a total of 30 diabetic patients with DFUs. The concentration of DNA extracted from 223 swab samples ranged from 2 to 80 ng/µl. PCR was used to detect and characterize the commonly detected microbial species *S. aureus* from DFUs. It was found that 44.8% of DFU swab samples were positive for the *mca* gene confirming the presence of *S. aureus* in these samples. All the *S. aureus* positive samples were examined further for the presence of MRSA by targeting the *mecA* gene. 25% of *S. aureus* positive samples were found to be MRSA. None of the *S. aureus* positive samples were positive for PVL. The *alpha toxin* gene was detected in 85% of the *S. aureus* positive samples, and the *exfA* gene was detected in 61% of the *S. aureus* positive samples. For the *fnbA* and *fnbB* genes, 71% and 74% of the *S. aureus* positive samples were positive for these two genes (Figure 1).

![Figure 1: Methicillin resistance and virulence profile of *Staphylococcus aureus* present in diabetic foot ulcerations.](image-url)
DISCUSSION

From the 30 patients recruited, 223 DFU swab samples were analyzed for the presence of *S. aureus*. The majority of previous studies have documented that *S. aureus* is the most commonly isolated Gram-positive bacteria from infected DFU. An Indian study showed that *S. aureus* was present in 21% of a total of 112 samples. Our results show that 66.6% of diabetic patients had *S. aureus* in their foot ulcers, and 44.8% of all the DFU swab samples were positive for *S. aureus*. This data are similar to what has been reported previously in a study performed at the Royal Melbourne Hospital in 2009 by Yates et al., however, their study used traditional culture-based methods.

*PVL*: Panton-Valentine leukocidin, *exfA*: Exfoliatin factor A, *fnbA*: Fibronectin factor A, *fnbB*: Fibronectin factor B, *S. aureus*: Staphylococcus aureus

**Table 1: Prevalence of *S. aureus* in DFUs.**

| Country | *S. aureus* prevalence (%) in infected DFUs | MRSA prevalence (%) in infected DFUs | References |
|---------|------------------------------------------|---------------------------------------|------------|
| USA     | 35.5                                     | 12.0                                  | Ge et al., 2002 |
| Santa Monica | 76.0                                    | 20.0                                  | Goldstein et al., 1996 |
| UAE     | 28.0                                     | 8.1                                   | El-Tahawy., 2000 |
| UK      | 48.3                                     | 30.2                                  | Tentolouris et al., 1999 |
| Kuwait  | 38.4                                     | 5.9                                   | Abdulrazak et al., 2005 |
| UK      | 42.0                                     | 19.0                                  | Stanaway et al., 2007 |
| Spain   | 47.5                                     | 19.9                                  | Aragón-Sánchez., 2008 |
| France  | 36                                       | 19.7                                  | Richard et al., 2008 |
| India   | 75                                       | 60                                    | Mehta et al., 2014 |

*S. aureus*: Staphylococcus aureus, DFU: Diabetic foot ulceration, MRSA: Methicillin resistant *S. aureus*

**Table 2: Oligonucleotide primers used in this study.**

| Target species | Gene | Forward primer | Reverse primer | Reference |
|----------------|------|----------------|----------------|-----------|
| *S. aureus*    | nucA | 5’GCCGATGGTAGGG TGATACGGTTT3’ | 5’AGCCAAGCCTTTGA CGAACTAAAC3’ | Huygens et al., 2006 |
| *S. aureus*    | mecA | 5’GATCGCAACGG TTAATTTATTTTGG3’ | 5’GCTTGTGTTCTTTCT GCATTCCT3’ | Huygens et al., 2006 |
| *PVL*          |      | 5’TATCTCTAACCC GTTGTCAAGGT3’ | 5’TGCTTTCAACA TCCCAACC3’ | Huygens et al., 2006 |
| *alpha-toxin*  |      | 5’GACCCAGCAATTG TACCTTTCT3’ | 5’GCTAATGCCGC AGATTCCTG3’ | Unpublished (Huygens et al.) |
| *exfA*         |      | 5’GCCGCTATAAACAC TTTGATAA3’ | 5’CAGGACTAGTC TTAGAAT3’ | Unpublished (Huygens et al.) |
| *fnbA*         |      | 5’CCACCTGGGGTTT GTATCTTCTTC3’ | 5’GATTACCAACACGC TATAGGTCGTG3’ | Unpublished (Huygens et al.) |
| *fnbB*         |      | 5’CGTGACCATTTTCA GTTCTAAACC3’ | 5’GATACAAACCC AGGTGTGGG3’ | Unpublished (Huygens et al.) |

PVL: Panton-Valentine leukocidin, *exfA*: Exfoliatin factor A, *fnbA*: Fibronectin factor A, *fnbB*: Fibronectin factor B, *S. aureus*: Staphylococcus aureus

**Table 2: Oligonucleotide primers used in this study.**

**Table 2: Oligonucleotide primers used in this study.**

| Target species | Gene | Forward primer | Reverse primer | Reference |
|----------------|------|----------------|----------------|-----------|
| *S. aureus*    | nucA | 5’GCCGATGGTAGGG TGATACGGTTT3’ | 5’AGCCAAGCCTTTGA CGAACTAAAC3’ | Huygens et al., 2006 |
| *S. aureus*    | mecA | 5’GATCGCAACGG TTAATTTATTTTGG3’ | 5’GCTTGTGTTCTTTCT GCATTCCT3’ | Huygens et al., 2006 |
| *PVL*          |      | 5’TATCTCTAACCC GTTGTCAAGGT3’ | 5’TGCTTTCAACA TCCCAACC3’ | Huygens et al., 2006 |
| *alpha-toxin*  |      | 5’GACCCAGCAATTG TACCTTTCT3’ | 5’GCTAATGCCGC AGATTCCTG3’ | Unpublished (Huygens et al.) |
| *exfA*         |      | 5’GCCGCTATAAACAC TTTGATAA3’ | 5’CAGGACTAGTC TTAGAAT3’ | Unpublished (Huygens et al.) |
| *fnbA*         |      | 5’CCACCTGGGGTTT GTATCTTCTTC3’ | 5’GATTACCAACACGC TATAGGTCGTG3’ | Unpublished (Huygens et al.) |
| *fnbB*         |      | 5’CGTGACCATTTTCA GTTCTAAACC3’ | 5’GATACAAACCC AGGTGTGGG3’ | Unpublished (Huygens et al.) |

PVL: Panton-Valentine leukocidin, *exfA*: Exfoliatin factor A, *fnbA*: Fibronectin factor A, *fnbB*: Fibronectin factor B, *S. aureus*: Staphylococcus aureus

**DISCUSSION**

From the 30 patients recruited, 223 DFU swab samples were analyzed for the presence of *S. aureus*. The majority of previous studies have documented that *S. aureus* is the most commonly isolated Gram-positive bacteria from infected DFU. An Indian study showed that *S. aureus* was present in 21% of a total of 112 samples. Our results show that 66.6% of diabetic patients had *S. aureus* in their foot ulcers, and 44.8% of all the DFU swab samples were positive for *S. aureus*. This data are similar to what has been reported previously in a study performed at the Royal Melbourne Hospital in 2009 by Yates et al., however, their study used traditional culture-based methods.

*S. aureus* has a number of virulence factors that facilitates the infection of soft tissues and bones. PVL is one of these virulence traits, and it seems to be associated with severely infected DFUs. In our study, none of the DFU patient samples were positive for PVL. Alpha-toxin is considered to be the most renowned *S. aureus* toxin and it has cytolytic activity. Its role in DFU infection is not well documented in the literature. We found that this toxin was present in 85% of *S. aureus* positive DFU swab samples. One of the previous studies have reported that the *exfA* gene was absent in their DFU samples. In our study, *exfA* was detected in 61% of the *S. aureus* positive DFU swab samples. *fnbA* and *fnbB* are members of microbial surface components recognizing adhesive matrix molecules family and mediate *S. aureus* adhesion to the host cell. In our study, *fnbA* gene was present in 71% of *S. aureus* positive DFU swab samples and the *fnbB* gene was present in 74% of *S. aureus* positive DFU swab samples.

DFUs are found to be increasingly inhabited with MRSA. A major health threat to the hospital and community setting is the increasing frequency of MRSA isolation from DFU. The majority of findings have shown that the prevalence of MRSA among diabetic patients with infected foot ulcers is 15-30%. In the United Kingdom, a study was conducted in which 30% of all cultured DFUs had MRSA. This MRSA colonization was linked to prior antibiotic usage, and it
adversely affected the wound healing process. In our study, we have found that 25% of all the S. aureus positive samples were MRSA. This trend is similar to that found by Yates et al. (2009), who isolated MRSA from 23% of DFUs. The factors predisposing to MRSA infection include chronic duration of DFU and prolonged use of antibiotics.

The rationale for targeting only S. aureus in our study is based on its increasing prevalence in DFUs, as described by previously published studies (Table 2). Our study reports the prevalence of S. aureus, MRSA and associated S. aureus virulence factors using molecular methods. To the best of our knowledge, this is the first Queensland study which has used molecular methods to characterize the virulence and methicillin resistance traits of S. aureus associated with DFUs.

ACKNOWLEDGMENTS

We acknowledge the assistance of Dr. Melissa Fernandez and Mr. Arnulf Compay for sample collection and preparation of the ethics application.

Funding: Australia-India Strategic Research Fund (AISRF) Conflict of interest: None declared Ethical approval: Approval was obtained from the QUT’s Ethics Committee prior to the commencement of this study

REFERENCES

1. Mendes JJ, Marques-Costa A, Vilela C, Neves J, Candeias N, Cavaco-Silva P, et al. Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res Clin Prat. 2012;95(1):153-61.
2. Eleftheriadou I, Tentolouris N, Argiana V, Jude E, Boulton AJ. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs. 2010;70(14):1785-97.
3. Pappu AK, Sinha A, Johnson A. Microbiological profile of diabetic foot ulcer. Calicut Med J. 2011;9:1-4.
4. Frykberg RG. An evidence-based approach to diabetic foot infections. Am J Surg. 2003;186(S5A):44S-54.
5. Roberts AD, Simon GL. Diabetic foot infections: the role of microbiology and antibiotic treatment. Semin Vasc Surg. 2012;25(2):75-81.
6. Kandemir O, Akbay E, Sahin E, Milcan A, Gen R. Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect. 2007;54(5):439-45.
7. Dowd SE, Wolcott RD, Sun Y, McKeehan T, Smith E, Rhoads D. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One. 2008;3(10):e3326.
8. Zubair M, Malik A, Ahmad J. Incidence, risk factors for amputation among patients with diabetic foot ulcer in a North Indian tertiary care hospital. Foot (Edinb). 2012;22(1):24-30.
9. Crouzet J, Lavigne JP, Richard JL, Sotto A, Nimes University Hospital Working Group on the Diabetic Foot (GP30). Diabetic foot infection: a critical review of recent randomized clinical trials on antibiotic therapy. Int J Infect Dis. 2011;15(9):e601-10.
10. Murali TS, Paul B, Parikh H, Singh RP, Kavitha S, Bhat MK, et al. Genome sequences of four clinical Staphylococcus aureus strains with diverse drug resistance profiles isolated from diabetic foot ulcers. Genome Announc. 2014;2(2).
11. Zubair M, Malik A, Ahmad J. Prevalence of metallo-ß-lactamase-producing Pseudomonas aeruginosa isolated from diabetic foot ulcer patients. Diabetes Metab Syndr. 2011;5(2):90-2.
12. Gadeppalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care. 2006;29(8):1727-32.
13. Basu S, Ramchuran Panray T, Bali Singh T, Gulati AK, Shukla VK. A prospective, descriptive study to identify the microbiological profile of chronic wounds in outpatients. Ostomy Wound Manage. 2009;55(1):14-20.
14. Chand G, Mishra AK, Kumar S, Agarwal A. Diabetic foot. Clinical Queries. Nephrology. 2012;0102:144-50.
15. Richard JL, Sotto A, Jourend N, Combescur E, Vannereau D, Rodier M, et al. Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metab. 2008;34:363-9.
16. Gardner SE, Hillis SL, Heilmann K, Segre JA, Grice EA. The neuropathic diabetic foot ulcer microbiome is associated with clinical factors. Diabetes. 2013;62(3):923-30.
17. Yates C, May K, Hale T, Allard B, Rowlings N, Freeman A, et al. Wound chronicity, inpatient care, and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care. 2009;32(10):1907-9.
18. Ambrosh A, Haeffner S, Jude E, Lobmann R. Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focussing on methicillin-resistant Staphylococcus aureus. Int Wound J. 2011;8(6):567-77.
19. Otto M. Staphylococcus aureus toxins. Curr Opin Microbiol. 2014;17:32-7.
20. Djahmi N, Messad N, Nedjai S, Moussaoui A, Mazouz D, Richard JL, et al. Molecular epidemiology of Staphylococcus aureus strains isolated from inpatients with infected diabetic foot ulcers in an Algerian University Hospital. Clin Microbiol Infect. 2013;19(9):E398-404.
21. Bowling FL, Jude EB, Boulton AJ. MRSA and diabetic foot wounds: contaminating or infecting organisms? Curr Diab Rep. 2009;9(6):440-4.
22. Goldstein EJ, Citron DM, Nesbit CA. Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from infected cases. Diabetes Care. 1996;19(6):638-41.
23. Lipsky BA, Richard JL, Lavigne JP. Diabetic foot ulcer microbiome: one small step for molecular microbiology one giant leap for understanding diabetic foot ulcers? Diabetes. 2013;62(3):679-81.
24. Huygens F, Inman-Bamber J, Nimmo GR, Munchhof W, Schooneveldt J, Harrison B, et al. Staphylococcus aureus genotyping using novel real-time PCR formats. J Clin Microbiol. 2006;44(10):3712-9.
25. Ge Y, MacDonald D, Hatt H, Lipsky B, Zasloff M, Holroyd K. Microbiological profile of infected diabetic foot ulcers. Diabet Med. 2002;19(12):1032-4.
26. El-Tahawy AT. Bacteriology of diabetic foot. Saudi Med J. 2000;21(4):344-7.
27. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med. 1999;16(9):767-71.
28. Abdulrazak A, Bitar ZI, Al-Shamali AA, Mobasher LA. Bacteriological study of diabetic foot infections. J Diabetes Complications. 2005;19(3):138-41.

29. Stanaway S, Johnson D, Moulik P, Gill G. Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res Clin Pract. 2007;75(1):47-50.

30. Aragón-Sánchez FJ, Cabrera-Galván JJ, Quintana-Marrero Y, Hernández-Herrero MJ, Lázaro-Martínez JL, García-Morales E, et al. Outcomes of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement. Diabetologia. 2008;51(11):1962-70.

31. Mehta VJ, Kikani KM, Mehta SJ. Microbiological profile of diabetic foot ulcers and its antibiotic susceptibility pattern in a teaching hospital, Gujarat. Int J Basic Clin Pharmacol. 2014;3:92-5.

doi: 10.5455/2319-2003.ijbcp20141201
Cite this article as: Sandhu S, Rathnayake IU, Huygens F. Prevalence of methicillin resistance and virulence determinants of Staphylococcus aureus in diabetic foot ulcers. Int J Basic Clin Pharmacol 2014;3:978-82.